{"name":"Institut Bergonié","slug":"institut-bergoni","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"At the discretion of the investigator","genericName":"At the discretion of the investigator","slug":"at-the-discretion-of-the-investigator","indication":"At the discretion of the investigator","status":"phase_3"},{"name":"Combination of trabectedin with durvalumab","genericName":"Combination of trabectedin with durvalumab","slug":"combination-of-trabectedin-with-durvalumab","indication":"Other","status":"phase_1"},{"name":"Phase 1: Trabectedin","genericName":"Phase 1: Trabectedin","slug":"phase-1-trabectedin","indication":"Other","status":"phase_1"},{"name":"Phase 2 : Avelumab","genericName":"Phase 2 : Avelumab","slug":"phase-2-avelumab","indication":"Other","status":"phase_1"},{"name":"undefined","genericName":"undefined","slug":"undefined","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Ifosfamide or dacarbazine","genericName":"Ifosfamide or dacarbazine","slug":"ifosfamide-or-dacarbazine","indication":"Soft tissue sarcoma (ifosfamide component)","status":"phase_3"},{"name":"target treatment","genericName":"target treatment","slug":"target-treatment","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"marketed"}]}],"pipeline":[{"name":"At the discretion of the investigator","genericName":"At the discretion of the investigator","slug":"at-the-discretion-of-the-investigator","phase":"phase_3","mechanism":"The mechanism of this drug is not specified.","indications":["At the discretion of the investigator"],"catalyst":""},{"name":"Combination of trabectedin with durvalumab","genericName":"Combination of trabectedin with durvalumab","slug":"combination-of-trabectedin-with-durvalumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ifosfamide or dacarbazine","genericName":"Ifosfamide or dacarbazine","slug":"ifosfamide-or-dacarbazine","phase":"phase_3","mechanism":"Ifosfamide and dacarbazine are alkylating agents that cross-link DNA to prevent cancer cell replication, while dacarbazine also acts as a prodrug requiring metabolic activation.","indications":["Soft tissue sarcoma (ifosfamide component)","Melanoma (dacarbazine component)","Lymphoma (both agents)"],"catalyst":""},{"name":"Phase 1: Trabectedin","genericName":"Phase 1: Trabectedin","slug":"phase-1-trabectedin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Phase 2 : Avelumab","genericName":"Phase 2 : Avelumab","slug":"phase-2-avelumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"target treatment","genericName":"target treatment","slug":"target-treatment","phase":"marketed","mechanism":"This drug targets the CDK4/6 pathway to inhibit cancer cell proliferation.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","Hormone receptor-positive, HER2-negative early breast cancer"],"catalyst":""},{"name":"undefined","genericName":"undefined","slug":"undefined","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxONVZna3VDaldKTmVRRldlS3YzVlBneFRkeXBXSy12QWItbkJWYnJkcHFnamFKcU1aWWNPdkdSVUNNYzF1QkR2NEtGemtDMnJ4YXJRaEE3a2k4bWx4aU9NcEdDalZhOGRNcDdMMHdQSllZOWJPWGNrdEVuaGRtNllxQ1JuSWhqSjZrNVZNbXNaX3VxTzdBaWlIT0dTaHYzYndxRjB0YjFRWjBSUGFFZnRUTlZuQ0JPaW1HLTM0bVdpZVBkMnJBR1A5bWY4dXpFckc5endiSw?oc=5","date":"2025-07-23","type":"pipeline","source":"European Medical Journal","summary":"Luteinising Hormone-Releasing Hormone Antagonists in Prostate Cancer: Myths and Facts - European Medical Journal","headline":"Luteinising Hormone-Releasing Hormone Antagonists in Prostate Cancer: Myths and Facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOTWcwMm5pcFRDa0hmeWdXYWxhSDBqQldhM0t2SGVtUHl6QkxsUXlqNEJsMTFTcXpXWEYyY0x5NEdVSVpPczVzcUQ0QmdOMzkteGYwTEFPc2tlOTBaSnJfRW5ZbE5FYWo2MW1OcmhOUzd0OWVhUkZpUzZ1TFYwZk9ucnlmZmo?oc=5","date":"2020-02-25","type":"pipeline","source":"gustaveroussy.fr","summary":"Pr Antoine Italiano (institut Bergonié) joins Gustave Roussy to head the precision oncology program - gustaveroussy.fr","headline":"Pr Antoine Italiano (institut Bergonié) joins Gustave Roussy to head the precision oncology program","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":2,"phase_1":3,"marketed":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}